Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 3, 2015

View Archived Issues

Alios Biopharma starts first-in-human study of HCV polymerase inhibitor AL-704

Novavax reports data from phase II trial of quadrivalent seasonal influenza vaccine

arGEN-X and University of Bern to develop ARGX-110-based combination therapies

University of Sydney to study Cymerus stem cells in heart disease models

Heptares to use MorphoSys antibody discovery technology against GPCR target

D-Pharm reports results from pilot trial of DP-b99 in acute pancreatitis

Filgotinib meets key efficacy endpoints in phase IIb DARWIN 1 study

Eisai and Halozyme sign collaboration agreement to investigate eribulin and PEGPH-20

Beijing Normal University patents technetium complexes for imaging

Coferon discloses Bcr-Abl tyrosine-kinase ligands

FDA accepts IND for EDO-S101 in patients with hematologic malignancies and solid tumors

KannaLife Sciences describes neuroprotectants

Aurigene Discovery Technologies divulges IRAK-4 inhibitors

KT&G Life Sciences develops NQO1 modulators

Alios Biopharma starts phase I drug interaction study for AL-335

AstraZeneca and Isis Pharmaceuticals form second antisense therapy collaboration

Sanofi profiles pipeline progress of second quarter 2015

Novel apelin receptor agonist shows promise as vasodilator

Perjeta regimen approved in E.U. for use before surgery in early-stage breast cancer

CTLA4-targeted therapies show promise for the treatment of LRBA deficiency

Allergan's AGN-223575 enters phase II study in dry eye

Biocad initiates phase I trial comparing adalimumab biosimilar to Humira

Anti-GD2 antibody enters phase II trial in osteosarcoma

TiGenix acquires Coretherapix

ORAI1 inhibitors show potential for the treatment of pancreatitis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...